Cognetivity Neurosciences Ltd.

CGN

CA19243C1005

Advanced Medical Equipment & Technology

Market Closed - Canadian Securities Exchange Other stock markets 01:52:01 2024-04-25 pm EDT			5-day change	1st Jan Change
0.02 ^CAD	0.00%		0.00%	+33.33%

2023	Cognetivity Neurosciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	CI
2023	Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in funding	CI

Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in funding

October 16, 2023

On October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investor

Latest news about Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 28	CI
Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in funding	23-10-16	CI
Cognetivity Neurosciences Ltd. and Uc Health Partner to Improve Early Detection of Cognitive Impairment in Usa	23-10-11	CI
Cognetivity Neurosciences Ltd. Announces Collaboration with the Mediclinic Group	23-10-03	CI
Cognetivity Neurosciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-29	CI
Cognetivity Neurosciences Ltd. announced that it expects to receive CAD 0.01 million in funding	23-09-14	CI
Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's Disease	23-07-07	CI
Cognetivity Neurosciences Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-29	CI
Clairvo Technologies, Inc. Announces Strategic Partnership with Cognetivity Neurosciences, Inc	23-06-13	CI
Cognetivity Neurosciences Ltd. Reports Earnings Results for the Full Year Ended January 31, 2023	23-06-09	CI
Cognetivity Neurosciences Ltd. Auditor Raises 'Going Concern' Doubt	23-06-08	CI
Cognetivity Neurosciences Ltd. Announces Collaboration with the Alzheimer's Society to Further Expand Its AI Algorithms	23-05-31	CI
Cognetivity Neurosciences Ltd. Announces Agreement with Mitsui Sumitomo Aioi Life Insurance of Japan to Provide CognICA Technology to Customers	23-04-25	CI
Cognetivity Neurosciences Ltd. Appoints Karimah Es Sabar to Its Board Director	23-04-20	CI
Cognetivity Neurosciences Enters Commercial Agreement with Conka	23-03-15	CI
Cognetivity Neurosciences Announces Commercial Deployment at Leading Psychiatry and Neurology Centre in UAE	23-02-23	CI
Cognetivity Announces Further Scientific Evidence of its AI-Powered CognICA(TM) Platform's Ability to Detect and Monitor Cognitive Impairment in Patients With Multiple Sclerosis	23-02-22	CI
Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATM	23-02-14	CI
Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying Therapy	23-01-24	CI
Cognetivity Neurosciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-16	CI
Cognetivity Neurosciences Ltd. Appoints Dr. Lance Black, MD, MBID as New Advisory Board Member	22-11-10	CI
Cognetivity Neurosciences Ltd. announced that it has received CAD 4.502478 million in funding from First Energy Bank B.S.C. (C)	22-10-26	CI
Cognetivity Neurosciences Ltd. announced that it expects to receive CAD 3 million in funding from First Energy Bank B.S.C. (C)	22-10-06	CI
Cognetivity Neurosciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-29	CI
Cognetivity Neurosciences Ltd. Announces Commercial Pilot with Large US Healthcare Provider	22-09-20	CI

Chart Cognetivity Neurosciences Ltd.

Duration

Period

More charts

Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Companyâs ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-04 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
COGNETIVITY NEUROSCIENCES LTD.	+33.33%	1.37M
VEEVA SYSTEMS INC.	+4.36%	32.47B
PRO MEDICUS LIMITED	+16.51%	7.45B
SECTRA AB	+21.38%	3.89B
EVOLENT HEALTH, INC.	-16.29%	3.17B
OMNICELL, INC.	-25.96%	1.28B
LUNIT INC.	-36.14%	1.09B
B-SOFT CO.,LTD.	-35.42%	902M
SIMULATIONS PLUS, INC.	-0.13%	893M
VERADIGM INC.	-24.12%	857M

Medical Software & Technology Services